List of Excipients in Branded Drug FLUOCINONIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alvogen Inc	FLUOCINONIDE	fluocinonide	47781-569	GLYCERYL MONOSTEARATE
Alvogen Inc	FLUOCINONIDE	fluocinonide	47781-569	PETROLATUM
Alvogen Inc	FLUOCINONIDE	fluocinonide	47781-569	PROPYLENE CARBONATE
Alvogen Inc	FLUOCINONIDE	fluocinonide	47781-569	PROPYLENE GLYCOL
Alvogen Inc	FLUOCINONIDE	fluocinonide	47781-569	WHITE WAX

Generic Drugs Containing FLUOCINONIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	fluocinonide	0093-0263	CETYL ALCOHOL
Teva Pharmaceuticals USA Inc	fluocinonide	0093-0263	CITRIC ACID MONOHYDRATE
Teva Pharmaceuticals USA Inc	fluocinonide	0093-0263	MINERAL OIL
Teva Pharmaceuticals USA Inc	fluocinonide	0093-0263	POLYSORBATE 60
Teva Pharmaceuticals USA Inc	fluocinonide	0093-0263	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in FLUOCINONIDE?

# Of NDCs	Excipient
31	1,2,6-HEXANETRIOL
25	ALCOHOL
31	ANHYDROUS CITRIC ACID
1	CARBOMER HOMOPOLYMER TYPE B
26	CARBOMER HOMOPOLYMER TYPE C

Fluocinonide Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Fluocinonide is an established high-potency topical corticosteroid with limited active-ingredient differentiation. The commercial opportunity is concentrated in excipient selection, delivery format, tolerability, cosmetic acceptability, adherence, and channel-specific positioning rather than in new chemical-entity protection. The strongest opportunities are low-irritation formulations for sensitive skin, scalp delivery, preservative-minimized products, pediatric-oriented vehicles, and differentiated generic or 505(b)(2) products.

What is fluocinonide and how is it regulated?

Fluocinonide is a synthetic corticosteroid used topically for corticosteroid-responsive dermatoses, including inflammatory and pruritic skin conditions. U.S. products are generally available at 0.05% strength in creams, ointments, gels, solutions, and related topical vehicles. It is classified as a high-potency topical corticosteroid, although potency varies by formulation and vehicle.

The original Lidex product was approved by the FDA decades ago. Fluocinonide is now marketed by multiple generic manufacturers and is also available through branded or authorized-generic channels. The FDA has approved topical fluocinonide products through conventional drug applications and generic abbreviated new drug applications, depending on the product.

Attribute	Commercial position
Active ingredient	Fluocinonide
Typical strength	0.05%
Therapeutic class	High-potency topical corticosteroid
Common dosage forms	Cream, ointment, gel, solution
Primary indications	Corticosteroid-responsive dermatoses
Prescription status	Prescription drug in the U.S.
Reference brand	Lidex
Generic competition	Established
Biosimilar pathway	Not applicable
Main differentiation lever	Vehicle, delivery, tolerability, packaging, and adherence

Topical corticosteroids have formulation-dependent clinical performance. A cream, ointment, gel, and solution containing the same fluocinonide concentration can differ in absorption, drying behavior, occlusiveness, spreadability, residue, and patient acceptance. FDA labeling warns that systemic absorption can increase with large treatment areas, prolonged use, occlusion, damaged skin, and potent corticosteroids.[1]

What excipients are used in fluocinonide products?

Fluocinonide products use excipients to control solubility, dispersion, skin penetration, viscosity, evaporation, preservation, sensory properties, and physical stability. The exact composition depends on the manufacturer and dosage form.

Common excipient classes include:

Excipient class	Typical examples	Primary function
Solvents and humectants	Propylene glycol, alcohol, water	Solubilization, hydration, evaporation, penetration
Emollients	Mineral oil, petrolatum, fatty alcohols	Skin conditioning and occlusion
Gelling agents	Carbomers, cellulose derivatives	Viscosity and structured delivery
Emulsifiers	Polysorbates, sorbitan derivatives, fatty alcohols	Oil-in-water or water-in-oil emulsion stability
Preservatives	Parabens, phenoxyethanol, benzoate systems	Microbial control
pH modifiers	Citric acid, sodium citrate, hydroxides	pH adjustment and stability
Antioxidants and chelators	Depending on product	Oxidative and metal-ion control
Packaging-compatible agents	Silicone-related or low-migration materials	Product-packaging performance

DailyMed labeling shows that fluocinonide creams, ointments, gels, and solutions can contain different combinations of propylene glycol, mineral oil, petrolatum, fatty alcohols, carbomers, alcohol, polysorbates, preservatives, and purified water.[2-5] Formulation developers must treat each vehicle as a separate product rather than assuming that excipient substitution will preserve bioequivalence or skin performance.

Which excipients create the greatest formulation risk?

Propylene glycol is widely used in topical products as a solvent and humectant. It can improve drug solubilization and skin penetration, but it may cause irritation or allergic contact dermatitis in susceptible patients. This creates a commercial opening for propylene-glycol-reduced or propylene-glycol-free products, particularly for sensitive skin and repeated-use populations.

Alcohol can improve drying and scalp application, but it can sting on fissured, inflamed, or excoriated skin. Alcohol-containing solutions and gels may be commercially attractive for hairy areas but less acceptable for eczema-prone or pediatric skin.

Petrolatum and mineral oil support occlusion and moisturization. Their disadvantages are greasiness, clothing transfer, and low cosmetic elegance. They remain valuable for very dry or lichenified lesions, where occlusion may improve treatment performance.

Preservatives can improve multidose product stability but may create tolerability concerns. A preservative-free or preservative-minimized design can support premium positioning, although packaging and microbiological controls become more demanding.

Carbomer and cellulose-based gels can provide a non-greasy vehicle, but they may pill, feel tacky, or leave residue. Rheology must be optimized for application to scalp, folds, or large body surfaces.

What formulations are protected by fluocinonide excipient strategy?

No single excipient automatically creates a commercially defensible product. Protection usually depends on the combination of:

1. The active concentration and physical state.
2. The vehicle composition.
3. Particle size or drug dispersion.
4. pH and rheology.
5. Skin delivery performance.
6. Packaging and dose delivery.
7. Stability and preservative system.
8. Clinical or pharmacokinetic advantages.

A formulation patent may claim a specific combination of fluocinide, solvent, emulsifier, gelling agent, pH range, viscosity range, or delivery system. A stronger claim set may link the composition to a measurable outcome, such as improved deposition, reduced irritation, improved stability, or lower residue.

The most defensible formulation concepts are likely to involve:

• A low-irritation vehicle with reduced solvent load.
• A non-greasy emollient cream with improved spreadability.
• A scalp solution or foam with controlled evaporation.
• A spray or metered-dose system that reduces hand contact.
• A low-water or anhydrous formulation with improved microbial robustness.
• A formulation that improves delivery without increasing systemic exposure.
• A vehicle compatible with sensitive-skin or fragrance-free positioning.
• A package that delivers a reproducible amount per actuation.

Excipient-only patent claims are vulnerable when the selected ingredients are conventional and the claimed ranges are broad. Commercial value improves when the formulation produces evidence of an unexpected performance advantage.

How should an excipient strategy differ by dosage form?

Cream

Creams offer the broadest commercial platform. They can balance moisturization, spreadability, cosmetic acceptability, and moderate occlusion. The main development challenge is avoiding a heavy or greasy sensory profile while maintaining drug uniformity and stability.

A differentiated cream could target:

• Sensitive skin.
• Fragrance-free use.
• Lower sting.
• Reduced residue.
• Improved spread over large areas.
• Better compatibility with daily moisturizers.
• A preserved or preservative-minimized system.

Creams are likely to face the greatest generic competition because they are familiar to prescribers, pharmacists, and patients.

Ointment

Ointments provide strong occlusion and are suitable for dry, thickened, or scaly lesions. Petrolatum-based systems are technically straightforward, but they have limited cosmetic appeal. Commercial differentiation is more difficult unless the product improves washability, spreadability, clothing transfer, or dose control.

An ointment may be attractive in dermatology specialty channels where clinical performance is prioritized over cosmetic elegance.

Gel

Gels are useful when a nongreasy, fast-drying product is desired. They can be positioned for scalp, seborrheic areas, or patients who reject ointments. Alcohol and propylene glycol may improve drug solubilization but can reduce tolerability.

The key technical variables are tack, pilling, drying time, viscosity, and drug crystallization during storage.

Solution

Solutions are well suited to the scalp and other hairy areas. Their commercial value depends on a clean applicator, low drip, controlled evaporation, and low sting. A solution that dries rapidly without excessive alcohol odor could compete on patient convenience.

Packaging is important. A nozzle, dropper, or targeted applicator can reduce product waste and improve delivery to the scalp.

Foam, spray, and other advanced formats

Foams and sprays can create meaningful differentiation because they improve access to large, hairy, or difficult-to-reach areas. These products also support premium pricing and direct-to-consumer communication around ease of application.

The regulatory burden is higher. Developers must demonstrate container performance, delivered-dose uniformity, product stability, microbial quality, and, for aerosol systems, compatibility with propellants and packaging. A foam or spray may be better suited to a 505(b)(2) strategy than to a conventional generic pathway if the product has a materially different dosage form or delivery system.

What FDA regulatory pathway applies to a new fluocinonide formulation?

A conventional generic product may use an ANDA if it matches the reference product in active ingredient, strength, dosage form, route, and relevant performance requirements. A materially different vehicle, dosage form, delivery system, or clinical use can complicate ANDA eligibility.

A 505(b)(2) application may be considered when the sponsor relies partly on existing FDA findings but introduces a new formulation, delivery system, indication, or clinical feature. The commercial rationale must justify the additional development cost and potential regulatory requirements.

Key regulatory issues include:

• Product sameness and pharmaceutical equivalence.
• Comparative drug release.
• In vitro release testing.
• Skin permeation and deposition.
• Local tolerability.
• Irritation and sensitization.
• Microbiological quality.
• Preservative effectiveness.
• Container-closure performance.
• Stability under intended storage conditions.
• Systemic corticosteroid exposure.
• Pediatric labeling and use limitations.

The FDA’s topical dermatological guidance places substantial emphasis on comparative product performance and dermatopharmacokinetic or other locally relevant testing when appropriate.[6] A new vehicle cannot rely solely on chemical assay results if the vehicle materially affects skin delivery.

What is the Orange Book status of fluocinonide?

Fluocinonide is a mature generic product category. The Orange Book generally identifies reference-listed products and approved abbreviated products, but the commercial significance of Orange Book listings depends on the specific product and whether patents or regulatory exclusivity are listed.

Fluocinide products are not biologics and do not use the biosimilar pathway. Generic competition proceeds through the ANDA framework rather than an abbreviated biologics license application.

For a specific product, the relevant diligence points are:

Diligence item	Commercial implication
Reference-listed drug	Defines the primary generic comparison
Listed patents	May affect Paragraph IV timing
Pediatric exclusivity	Can delay approval or launch in limited circumstances
Formulation differences	May require a different regulatory strategy
Labeling limitations	Can constrain promotional claims
Product-specific exclusivity	May affect ANDA approval timing

When does fluocinonide lose exclusivity?

The original active-ingredient and reference-product exclusivity periods have long expired. Current commercial protection is not based on meaningful new-molecule exclusivity. It depends on product-level patents, formulation patents, regulatory exclusivity, trademarks, manufacturing know-how, and commercial execution.

Because fluocinide is an old topical corticosteroid with multiple approved generics, a new entrant should not assume that the active ingredient itself provides protection. The relevant question is whether a particular formulation or delivery system creates enforceable and commercially meaningful rights.

Which companies are challenging fluocinide products?

The market is characterized by multiple generic manufacturers rather than a small number of clearly identifiable branded challengers. Generic topical corticosteroids are often supplied by companies such as Taro, Glenmark, Perrigo, Fougera, Amneal, Sandoz, and other manufacturers, depending on product, strength, dosage form, and market period.

The competitive set changes by dosage form. A company may have approval for fluocinide cream but not ointment, gel, solution, or a differentiated delivery format. Channel supply, wholesaler contracts, shortage status, and pharmacy substitution can matter as much as the number of approved manufacturers.

Paragraph IV challenges are more relevant to any newly patented fluocinide formulation than to the old active ingredient. A formulation patent covering a premium product could attract an ANDA challenger if expected market value justifies litigation costs.

What patent litigation and settlement risks affect fluocinide?

The main litigation risks for a new fluocinide product are:

• Invalidity attacks against formulation claims.
• Non-infringement arguments based on excipient ranges.
• Obviousness challenges using prior topical corticosteroid formulations.
• Paragraph IV litigation involving a listed formulation patent.
• Trade-secret disputes over manufacturing processes.
• Antitrust exposure from delayed-entry or supply agreements.
• Patent-term uncertainty for newly developed delivery systems.

Settlement agreements could include launch dates, licenses, authorized-generic arrangements, or restrictions tied to formulation claims. Their value depends on the size of the target market and the breadth of the patent claims.

A sponsor should prioritize patents that cover measurable product attributes, such as a defined rheology profile, particle-size distribution, drug-release behavior, or delivery performance. Claims based only on the presence of familiar excipients are more exposed to invalidity and design-around strategies.

How strong is the patent estate for a new fluocinide formulation?

The patent estate for the old active ingredient is weak because the molecule is mature and genericized. A new product can still build a moderate or strong estate if it combines composition, process, delivery, and use claims.

Patent category	Potential strength
New chemical form of fluocinide	Usually limited unless technically distinct
Broad excipient combination	Low to moderate
Narrow composition with performance data	Moderate
Foam, spray, or metered delivery system	Moderate to strong
Manufacturing process	Moderate if difficult to replicate
Stability and impurity control	Moderate
New indication	Potentially strong if clinically supported
Packaging and applicator	Moderate, but easy design-around risk
Method of use	Variable and dependent on label and evidence

The most valuable combination is a differentiated dosage form with clinical or adherence data and a patent portfolio that covers both the product and its manufacturing process.

What commercial opportunities exist for fluocinide excipients?

Sensitive-skin positioning

A propylene-glycol-reduced, alcohol-free, fragrance-free cream could target patients who experience burning or irritation with conventional vehicles. The opportunity is strongest where prescribers need high-potency treatment but want a more acceptable base.

Scalp delivery

Scalp psoriasis, dermatitis, and other inflammatory scalp conditions create a clear need for non-greasy, low-drip delivery. A foam, spray, or controlled-flow solution could improve treatment adherence compared with ointments or heavy creams.

Pediatric and caregiver use

Pediatric use requires conservative positioning because high-potency corticosteroids carry greater risk of local and systemic adverse effects when used improperly. The commercial opportunity is not necessarily a lower-strength product. It may be a controlled-dose package, low-transfer vehicle, or formulation with clear dosing instructions.

Specialty pharmacy and dermatology clinics

A premium vehicle can be positioned around tolerability, application time, and patient adherence. Specialty dermatology channels may support higher prices than mass generic channels, provided the product has a credible clinical or usability advantage.

Contract manufacturing and licensing

Companies with expertise in semisolids, foams, topical aerosols, and dermatological packaging may license formulation platforms to generic manufacturers. The strongest licensing candidates are products with completed scale-up, stability, comparative performance, and regulatory documentation.

International markets

Regulatory requirements and reference products vary by country. The United States, European Union, Canada, Japan, and emerging markets may differ in accepted excipients, labeling, preservative requirements, and topical bioequivalence expectations. A formulation using globally familiar excipients can reduce development friction, but local regulatory assessment remains product-specific.

What manufacturing and intellectual-property barriers matter?

Semisolid manufacturing has several practical barriers:

• Uniform distribution of low-dose fluocinonide.
• Control of particle size and agglomeration.
• Emulsion stability.
• Prevention of crystallization.
• Consistent viscosity across batches.
• Homogeneous filling into tubes or pumps.
• Compatibility with plastic packaging.
• Microbial control in water-containing systems.
• Scale-up without changing skin delivery.

An apparently simple cream can require extensive process control. The manufacturing process may become a meaningful barrier if it produces a narrow particle-size distribution, controlled drug release, or superior stability that competitors cannot easily reproduce.

Packaging can also create a commercial advantage. Airless pumps, metered-dose systems, scalp applicators, and unit-dose packs may reduce contamination, improve dosing, and support adherence. Their patent value is strongest when the package is necessary to maintain product quality or deliver a defined dose.

How does fluocinide compare with competing topical corticosteroids?

Drug	Typical potency position	Common commercial formats	Main competitive issue
Fluocinide 0.05%	High	Cream, ointment, gel, solution	Mature generic competition
Betamethasone dipropionate	High to super-high, depending on vehicle	Cream, ointment, lotion, foam	Strong vehicle and potency differentiation
Clobetasol propionate	Super-high	Cream, ointment, foam, solution, shampoo	Premium specialty and scalp formats
Mometasone furoate	Medium to high	Cream, ointment, lotion	Broad use and cosmetic vehicles
Triamcinolone acetonide	Medium	Cream, ointment, lotion, spray	Lower-potency, high-volume generic competition
Desonide	Low	Cream, ointment, lotion, foam	Sensitive-skin and lower-potency positioning

Fluocinide competes most directly with betamethasone dipropionate and other high-potency corticosteroids. A new fluocinide product needs a clear reason to be selected, such as lower irritation, easier scalp application, better cosmetic properties, or a superior delivery device.

What generic launch scenarios exist for fluocinide?

A new entrant has four realistic commercial models:

1. Low-cost ANDA product competing on manufacturing efficiency and supply reliability.
2. Differentiated generic with improved vehicle characteristics.
3. 505(b)(2) product using a new foam, spray, or controlled-dose system.
4. Branded dermatology product supported by adherence, tolerability, or patient-experience data.

The lowest-risk model is a conventional cream or ointment, but price erosion is likely. The highest-value model is a differentiated delivery system, but it requires more development, regulatory, and commercial investment.

Public company filings generally do not isolate fluocinide revenue from broader dermatology portfolios. Revenue exposure should therefore be modeled from prescription volume, net price, dosage-form mix, payer substitution, wholesaler discounts, and expected generic erosion rather than from company-level disclosure.

Key Takeaways

• Fluocinide is a mature, genericized topical corticosteroid with little value in the old active ingredient alone.
• Excipient strategy is the primary route to differentiation.
• The strongest opportunities are scalp formats, low-irritation vehicles, preservative-minimized systems, and controlled-dose packaging.
• Propylene glycol, alcohol, preservatives, greasiness, residue, and poor scalp handling are practical formulation targets.
• Creams and ointments have lower development risk but greater price competition.
• Foams, sprays, and metered systems can command better commercial positioning but may require a 505(b)(2) strategy.
• Formulation patents are stronger when tied to measurable delivery, stability, tolerability, or usability outcomes.
• Fluocinide has no biosimilar risk because it is a small-molecule topical drug.
• Generic launch economics depend heavily on dosage form, supply reliability, payer substitution, and channel access.
• A credible product requires aligned formulation, packaging, manufacturing, regulatory, and patent strategies.

Frequently Asked Questions

Can propylene glycol-free fluocinide be commercially attractive?

Yes. A propylene-glycol-free formulation could target patients with irritation or contact sensitivity concerns, provided it maintains drug solubility, stability, uniformity, and comparable topical performance.

Is a fluocinide foam likely to receive premium pricing?

Potentially. A foam that improves scalp coverage, reduces residue, and dries quickly can support premium positioning, but pricing depends on clinical differentiation, payer coverage, and competing high-potency foams.

Can a new fluocinide cream qualify as a generic?

It may qualify for an ANDA if it meets applicable sameness and performance requirements. Material differences in vehicle, dosage form, delivery, or labeling may require a different regulatory pathway.

Are fluocinide formulation patents easy to design around?

Many broad excipient claims are vulnerable to design-around strategies. Narrow claims tied to specific performance ranges, manufacturing controls, or delivery systems are more defensible.

Does fluocinide have biosimilar competition?

No. Fluocinide is a small-molecule drug. Competition comes from generic topical products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Fluocinonide topical: Prescribing information. FDA labeling database.

2. DailyMed. (2024). Fluocinonide cream, 0.05%: Drug label. National Library of Medicine.

3. DailyMed. (2024). Fluocinonide ointment, 0.05%: Drug label. National Library of Medicine.

4. DailyMed. (2024). Fluocinonide topical solution, 0.05%: Drug label. National Library of Medicine.

5. DailyMed. (2024). Fluocinonide topical gel, 0.05%: Drug label. National Library of Medicine.

6. U.S. Food and Drug Administration. (2022). Assessing the in vitro performance of topical dermatological drug products. FDA guidance for industry.

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. 44th ed. FDA, Center for Drug Evaluation and Research.